|
1
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
|
2
|
Tucci A, Merli F, Fabbri A, Mancuso S, Sartori R, Storti S, Luminari S, Mammi C, Marcheselli L, Arcari A, Cavallo F, Zilioli VR, Bottelli C, Re A, Gini G, Cox MC, Puccini B, Pagani C, Balzarotti M, Spina M, Rossi G. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.95_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Tucci
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - F. Merli
- Azienda Unità Sanitaria Locale – IRCCS Hematology Unit Reggio Emilia Italy
| | - A. Fabbri
- zienda Ospedaliera Universitaria Senese and University of Siena Unit of Hematology Siena Italy
| | - S. Mancuso
- Department Pro.Mi.Se Univeristy of Palermo Haematology Division Palermo Italy
| | - R. Sartori
- Veneto Institute of Oncology IOV‐IRCCS Department of Clinical and Experimental Oncology Oncohematology Unit Castelfranco Veneto (TV) Italy
| | - S. Storti
- Università Cattolica Onco‐hematology Unit Campobasso‐Roma Italy
| | - S. Luminari
- University of Modena and Reggio Emilia Azienda Unità Sanitaria Locale – IRCCS Department CHIMOMO Hematology Unit Reggio Emilia Italy
| | - C. Mammi
- Gruppo Amici dell'Ematologia GRADE‐ Onlus Foundation Hematology Unit Reggio Emilia Italy
| | - L. Marcheselli
- Fondazione Italiana Linfomi Onlus Fondazione Italiana Linfomi Onlus Modena Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Cavallo
- University of Torino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - C. Bottelli
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - A. Re
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - G. Gini
- Azienda Ospedaliera Universitaria Ospedali Riuniti Division of Hematology Ancona Italy
| | - M. C. Cox
- Azienda Ospedaliera Universitaria S.Andrea Hematology Unit Roma Italy
| | - B. Puccini
- Careggi University Hospital Hematology Unit Firenze Italy
| | - C. Pagani
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - M. Balzarotti
- Humanitas Clinical Research Hospital‐IRCCS Department of Medical Oncology and Hematology Rozzano (MI) Italy
| | - M. Spina
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Division of Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - G. Rossi
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| |
Collapse
|
|
3
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
|
4
|
Spina M, Merli F, Puccini B, Cavallo F, Cabras M, Fabbri A, Angrilli F, Zilioli V, Marino D, Balzarotti M, Ladetto M, Cox M, Petrucci L, Arcari A, Gini G, Chiappella A, Hohaus S, Musuraca G, Merli M, Sartori R, Nassi L, Tani M, Re F, Flenghi L, Molinari A, Kovalchuk S, Bottelli C, Ferrero S, Dessì D, Cencini E, Pennese E, Marcheselli L, Mammi C, Luminari S, Tucci A. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.58_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Spina
- Division of Medical Oncology and Immune-related tumors; National Cancer Institute; Aviano (PN) Italy
| | - F. Merli
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - B. Puccini
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - M.G. Cabras
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - A. Fabbri
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - F. Angrilli
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | - V.R. Zilioli
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - D. Marino
- Medical Oncology 1; Veneto Institute of Oncology IOV IRCCS; Padova Italy
| | - M. Balzarotti
- Department of Medical Oncology and Hematology; Humanitas, Clinical and Research Hospital-IRCCS; Rozzano (MI) Italy
| | - M. Ladetto
- Division of Hematology; A.O. SS Antonio e Biagio and Cesare Arrigo; Alessandria Italy
| | - M.C. Cox
- Hematology Unit; AOU Sant'Andrea; Roma Italy
| | - L. Petrucci
- Institute of Hematology; Dept. of Translational and Precision Medicine “Sapienza”, University of Roma; Roma Italy
| | - A. Arcari
- Haematology Unit; Azienda AUSL; Piacenza Italy
| | - G. Gini
- Division of Haematology; Ospedali Riuniti; Ancona Italy
| | - A. Chiappella
- Division of Hematology; Città della Salute e della Scienza Hospital and University; Torino Italy
| | - S. Hohaus
- Catholic University of the Sacred Heart; University Policlinico Gemelli Foundation, IRCCS; Roma Italy
| | - G. Musuraca
- Department of Hematology; Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori; Meldola (FC) Italy
| | - M. Merli
- Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - R. Sartori
- Hematology Department; Castelfranco Veneto Regional Hospital; Castelfranco Veneto (TV) Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - M. Tani
- Department of Hematology; S. Maria delle Croci Hospital; Ravenna Italy
| | - F. Re
- Hematology and BMT Center; Azienda Ospedaliera, University of Parma; Parma Italy
| | - L. Flenghi
- Hematology; S. Maria della Misericordia Hospital; Perugia Italy
| | - A. Molinari
- Hematology Unit; Infermi Hospital; Rimini Italy
| | - S. Kovalchuk
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - C. Bottelli
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| | - S. Ferrero
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - D. Dessì
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - E. Cencini
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - E. Pennese
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | | | - C. Mammi
- GRADE; Gruppo Amici dell'Ematologia Foundation; Reggio Emilia Italy
| | - S. Luminari
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - A. Tucci
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| |
Collapse
|
|
5
|
Donati B, Casali M, Fama A, Puccini B, Zanelli M, Valli R, Santi R, Vergoni F, Ruffini A, Berti V, Rigacci L, Merli F, Ciarrocchi A, Luminari S. A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD. Hematol Oncol 2019. [DOI: 10.1002/hon.17_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- B. Donati
- Laboratory of Translational Research; AUSL IRCCS; Reggio Emilia Italy
| | - M. Casali
- Nuclear Medicine; AUSL IRCCS; Reggio Emilia Italy
| | - A. Fama
- Hematology; AUSL IRCCS; Reggio Emilia Italy
| | - B. Puccini
- Hematology; Azienda Ospedaliero Universitaria Careggi; Firenze Italy
| | - M. Zanelli
- Pathology; AUSL IRCCS; Reggio Emilia Italy
| | - R. Valli
- Pathology; AUSL IRCCS; Reggio Emilia Italy
| | - R. Santi
- Pathological Histology and Molecular Diagnostics; Azienda Ospedaliero Universitaria Careggi; Firenze Italy
| | - F. Vergoni
- Pathological Histology and Molecular Diagnostics; Azienda Ospedaliero Universitaria Careggi; Firenze Italy
| | - A. Ruffini
- Hematology; GRuppo Amici dell'Ematologia Foundation_GrADE; Reggio Emilia Italy
| | - V. Berti
- Nuclear Medicine; University of Firenze; Firenze Italy
| | - L. Rigacci
- Hematology and Stem Cell Transplant; AO San Camillo Forlanini, Roma and Hematology of Azienda Ospedaliero Universitaria Careggi; Firenze Italy
| | - F. Merli
- Hematology; AUSL IRCCS; Reggio Emilia Italy
| | - A. Ciarrocchi
- Laboratory of Translational Research; AUSL IRCCS; Reggio Emilia Italy
| | | |
Collapse
|
|
6
|
Cencini E, Puccini B, Rigacci L, Fabbri A, Kovalchuk S, Benelli G, Mannelli L, Carfagno T, Simontacchi G, Bocchia M, Bosi A. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- E. Cencini
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - B. Puccini
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - L. Rigacci
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - A. Fabbri
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - S. Kovalchuk
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - G. Benelli
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - L. Mannelli
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - T. Carfagno
- Radiotherapy; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - G. Simontacchi
- Radiotherapy; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| | - M. Bocchia
- Hematology; Azienda Ospedaliera Universitaria Senese & University of Siena; Siena Italy
| | - A. Bosi
- Hematology; Azienda Ospedaliera Universitaria Careggi; Florence Italy
| |
Collapse
|
|
7
|
Rigacci L, Perrone G, Nobili S, Kovalchuk S, Puccini B, Tassi R, Brugia M, Landini I, Mannelli L, Benelli G, Napoli C, Cencini E, Fabbri A, Iovino L, Petrini M, Birtolo S, Melosi A, Santini S, Bernardeschi P, Bosi A, Mini E. Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: An interim analysis of a multicenter prospective pharmacogenetic study. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - G. Perrone
- Dipartimento di Medicina Sperimentale e Clinica; University of Florence; Florence Italy
| | - S. Nobili
- Dipartimento di Scienze della Salute; University of Florence; Florence Italy
| | | | | | - R. Tassi
- Dipartimento di Medicina Sperimentale e Clinica; University of Florence; Florence Italy
| | - M. Brugia
- Dipartimento di Medicina Sperimentale e Clinica; University of Florence; Florence Italy
| | - I. Landini
- Dipartimento di Medicina Sperimentale e Clinica; University of Florence; Florence Italy
| | | | | | - C. Napoli
- Dipartimento di Scienze della Salute; University of Florence; Florence Italy
| | | | | | | | | | | | - A. Melosi
- Oncology; Ospedale Lucca; Lucca Italy
| | | | | | - A. Bosi
- Hematology; AOU Careggi; Florence Italy
| | - E. Mini
- Dipartimento di Medicina Sperimentale e Clinica; University of Florence; Florence Italy
| |
Collapse
|
|
8
|
Rigacci L, Puccini B, Zinzani P, Kovalchuk S, Broccoli A, Evangelista A, Gioia D, Mannelli L, Castagnoli A, Santoro A, Bonfichi M, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Borsatti E, Levis A. CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | | | - P. Zinzani
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - A. Broccoli
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - D. Gioia
- Hematology; Ospedale Alessandria; Alessandria Italy
| | | | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Milan Italy
| | | | - G. Rossi
- Hematology; Ospedale Brescia; Brescia Italy
| | | | - F. Zaja
- Hematology; Ospedale Udine; Udine Italy
| | - U. Vitolo
- Hematology; AOU Città della Salute; Torino Italy
| | - V. Pavone
- Hematology; Ospedale Tricase; Tricase Italy
| | - A. Pulsoni
- Hematology; Università la Sapienza; Rome Italy
| | - G. Gaidano
- Hematology; Università Novara; Novara Italy
| | - C. Stelitano
- Hematology; Ospedale Reggio Calabria; Reggio Calabria Italy
| | - F. Salvi
- Hematology; Ospedale Alessandria; Alessandria Italy
| | - C. Rusconi
- Hematology; Ospedale Niguarda Ca' Grande; Milan Italy
| | - M. Tani
- Hematology; Ospedale Ravenna; Ravenna Italy
| | | | | | - A. Levis
- Hematology; Ospedale Alessandria; Alessandria Italy
| |
Collapse
|
|
9
|
Baldini S, Carrai V, Puccini B, Rigacci L, Alterini R, Bosi A. Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions. Transfus Med 2014; 24:125-6. [PMID: 24720383 DOI: 10.1111/tme.12106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 12/16/2013] [Accepted: 01/11/2014] [Indexed: 11/30/2022]
Affiliation(s)
- S Baldini
- Haematology Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, 50134, Florence, Italy
| | | | | | | | | | | |
Collapse
|
|
10
|
Rigacci L, Puccini B, Iovino L, Martelli M, Finolezzi E, Di Lollo S, Doria M, Bosi A. Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma. J Chemother 2013; 23:227-31. [DOI: 10.1179/joc.2011.23.4.227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
|
11
|
Rigacci L, Scoccianti G, Puccini B, Campanacci D, Simontacchi G, Kovalchuk S, Fabbri E, Capanna R, Bosi A. Primary lymphoma of bone: single center experience. Drugs Cell Ther Hematol 2013. [DOI: 10.4081/dcth.2013.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
|
12
|
Rigacci L, Scoccianti G, Puccini B, Campanacci D, Simontacchi G, Kovalchuk S, Fabbri E, Capanna R, Bosi A. Primary lymphoma of bone: single center experience. Drugs Cell Ther Hematol 2013. [DOI: 10.4081/dcth.2013.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|